Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Identification of an Acquired Mutation in Jak2 Provides Molecular Insights into the Pathogenesis of Myeloproliferative Disorders

Identification of an Acquired Mutation in Jak2 Provides Molecular Insights into the Pathogenesis... Abstract Among tyrosine kinases, the Janus kinases (Jaks) are the only ones known to possess two kinase domains: a C-terminal functional kinase domain and a nonfunctional pseudokinase domain located just N-terminal to the functioning domain. The pseudokinase domain, or Jak homology domain 2 (JH2)—Jaks contain seven domains that are well-conserved by the four Jak family members—lacks a few key residues critical for catalytic activity. The function of the JH2 has remained a mystery, but recent results indicate that the JH2 domain of Jak2 may inhibit kinase activity. New intriguing observations reveal that the majority of individuals afflicted with polycythemia vera, essential thrombocythemia, or chronic idiopathic myelofibrosis (all members of the chronic myeloproliferative disorders family) share the V617F mutation of the Jak2 JH2 domain. Although the mutation occurs, to some degree, in the germ line, it more often presents as an acquired mutation. The mutation might cause a structural change sufficient to prevent negative regulators from binding and inhibiting the kinase, or could place the kinase in a constitutively “on” conformation. The identification of V617F now provides a molecular diagnostic indicator of several chronic myeloproliferative diseases. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Molecular Interventions Am. Soc for Pharma & Experimental Therapeutics

Identification of an Acquired Mutation in Jak2 Provides Molecular Insights into the Pathogenesis of Myeloproliferative Disorders

Identification of an Acquired Mutation in Jak2 Provides Molecular Insights into the Pathogenesis of Myeloproliferative Disorders

Molecular Interventions , Volume 5 (4): 211 – Aug 1, 2005

Abstract

Abstract Among tyrosine kinases, the Janus kinases (Jaks) are the only ones known to possess two kinase domains: a C-terminal functional kinase domain and a nonfunctional pseudokinase domain located just N-terminal to the functioning domain. The pseudokinase domain, or Jak homology domain 2 (JH2)—Jaks contain seven domains that are well-conserved by the four Jak family members—lacks a few key residues critical for catalytic activity. The function of the JH2 has remained a mystery, but recent results indicate that the JH2 domain of Jak2 may inhibit kinase activity. New intriguing observations reveal that the majority of individuals afflicted with polycythemia vera, essential thrombocythemia, or chronic idiopathic myelofibrosis (all members of the chronic myeloproliferative disorders family) share the V617F mutation of the Jak2 JH2 domain. Although the mutation occurs, to some degree, in the germ line, it more often presents as an acquired mutation. The mutation might cause a structural change sufficient to prevent negative regulators from binding and inhibiting the kinase, or could place the kinase in a constitutively “on” conformation. The identification of V617F now provides a molecular diagnostic indicator of several chronic myeloproliferative diseases.

Loading next page...
 
/lp/am-soc-for-pharma-experimental-therapeutics/identification-of-an-acquired-mutation-in-jak2-provides-molecular-WfAu7iqm0G

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Am. Soc for Pharma & Experimental Therapeutics
Copyright
Copyright © Molecular Interventions
ISSN
1534-0384
eISSN
1543-2548
DOI
10.1124/mi.5.4.4
pmid
16123535
Publisher site
See Article on Publisher Site

Abstract

Abstract Among tyrosine kinases, the Janus kinases (Jaks) are the only ones known to possess two kinase domains: a C-terminal functional kinase domain and a nonfunctional pseudokinase domain located just N-terminal to the functioning domain. The pseudokinase domain, or Jak homology domain 2 (JH2)—Jaks contain seven domains that are well-conserved by the four Jak family members—lacks a few key residues critical for catalytic activity. The function of the JH2 has remained a mystery, but recent results indicate that the JH2 domain of Jak2 may inhibit kinase activity. New intriguing observations reveal that the majority of individuals afflicted with polycythemia vera, essential thrombocythemia, or chronic idiopathic myelofibrosis (all members of the chronic myeloproliferative disorders family) share the V617F mutation of the Jak2 JH2 domain. Although the mutation occurs, to some degree, in the germ line, it more often presents as an acquired mutation. The mutation might cause a structural change sufficient to prevent negative regulators from binding and inhibiting the kinase, or could place the kinase in a constitutively “on” conformation. The identification of V617F now provides a molecular diagnostic indicator of several chronic myeloproliferative diseases.

Journal

Molecular InterventionsAm. Soc for Pharma & Experimental Therapeutics

Published: Aug 1, 2005

There are no references for this article.